4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 151 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2024. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $1,991,250 | – | 62,500 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 4,400,000 | $92,356,000 | 5.88% |
| Deep Track Capital, LP | 4,061,401 | $85,248,807 | 2.54% |
| BVF INC/IL | 3,922,413 | $82,331,449 | 2.31% |
| Decheng Capital LLC | 347,835 | $7,301,057 | 2.24% |
| Novo Holdings A/S | 1,400,000 | $29,386,000 | 1.71% |
| Eagle Health Investments LP | 462,911 | $9,716,502 | 1.70% |
| Opaleye Management Inc. | 345,750 | $7,257,293 | 1.66% |
| RA Capital Management | 5,098,211 | $107,011,449 | 1.42% |
| Redmile Group, LLC | 1,073,435 | $22,531,401 | 1.36% |
| Casdin Capital, LLC | 800,000 | $16,792,000 | 1.29% |